Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer

Reversible centriole depletion with an inhibitor of Polo-like kinase 4

Yao Liang Wong, John V. Anzola, Robert L. Davis et al. · Science · 2015 · 500 citations · Full text

Life Sciences, Cancer Biology, Cell Biology +17

The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1<i>R</i>,2<i>S</i>)-2-(3-((<i>E</i>)-4-(((<i>cis</i>)-2,6-Dimethylmorpholino)methyl)styryl)-1<i>H</i>-indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent

Peter B. Sampson, Yong Liu, Bryan Forrest et al. · Journal of Medicinal Chemistry · 2014 · 171 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

TRIM37 controls cancer-specific vulnerability to PLK4 inhibition

Franz Meitinger, Midori Ohta, Kian-Yong Lee et al. · Nature · 2020 · 156 citations · Full text

Medicine, Molecular Biology, Oncology +14

VX-680 Inhibits Aurora A and Aurora B Kinase Activity in Human Cells

Rebecca K. Tyler, Natalia Shpiro, Rodolfo Márquez et al. · Cell Cycle · 2007 · 118 citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacological and Functional Comparison of the Polo-like Kinase Family:  Insight into Inhibitor and Substrate Specificity

Eric F. Johnson, Kent D. Stewart, Keith W. Woods et al. · Biochemistry · 2007 · 115 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14